Fresenius Medical Care (NYSE:FMS - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 6th. Analysts expect the company to announce earnings of $0.45 per share and revenue of $4.71 billion for the quarter.
Fresenius Medical Care Trading Up 2.4 %
Fresenius Medical Care stock traded up $0.60 during trading hours on Friday, hitting $25.62. The stock had a trading volume of 1,147,884 shares, compared to its average volume of 320,379. The stock has a market cap of $15.03 billion, a price-to-earnings ratio of 21.17, a P/E/G ratio of 0.76 and a beta of 0.93. The company has a quick ratio of 1.02, a current ratio of 1.37 and a debt-to-equity ratio of 0.42. The business's 50 day simple moving average is $24.11 and its 200-day simple moving average is $23.14. Fresenius Medical Care has a one year low of $17.93 and a one year high of $26.04.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on FMS shares. StockNews.com raised shares of Fresenius Medical Care from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 5th. Truist Financial lifted their target price on Fresenius Medical Care from $23.00 to $25.00 and gave the stock a "hold" rating in a report on Monday, January 6th.
Read Our Latest Stock Analysis on FMS
Fresenius Medical Care Company Profile
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Further Reading
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
